Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MCRB 
Seres Therapeutics Inc (MCRB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/13/2025: MCRB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -73.85% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 117.90M USD | Price to earnings Ratio - | 1Y Target Price 3.82 |
Price to earnings Ratio - | 1Y Target Price 3.82 | ||
Volume (30-day avg) 814604 | Beta 2.17 | 52 Weeks Range 0.54 - 1.53 | Updated Date 04/2/2025 |
52 Weeks Range 0.54 - 1.53 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.43% | Return on Equity (TTM) -1556.28% |
Valuation
Trailing PE - | Forward PE 1.54 | Enterprise Value 178748388 | Price to Sales(TTM) 390.27 |
Enterprise Value 178748388 | Price to Sales(TTM) 390.27 | ||
Enterprise Value to Revenue 805.87 | Enterprise Value to EBITDA -2.07 | Shares Outstanding 174359008 | Shares Floating 128451837 |
Shares Outstanding 174359008 | Shares Floating 128451837 | ||
Percent Insiders 13.02 | Percent Institutions 36.18 |
Analyst Ratings
Rating 3.86 | Target Price 3.87 | Buy - | Strong Buy 4 |
Buy - | Strong Buy 4 | ||
Hold 1 | Sell 2 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Seres Therapeutics Inc
Company Overview
History and Background
Seres Therapeutics, Inc. was founded in 2010. It is a microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by modulating the function of the human microbiome. A significant milestone was the FDA approval of VOWST in 2023.
Core Business Areas
- Microbiome Therapeutics: Focuses on developing and commercializing microbiome-based therapies for various diseases.
Leadership and Structure
Eric Shaff is the President and CEO. The company has a typical corporate structure with a board of directors and various departments responsible for research and development, manufacturing, commercialization, and administration.
Top Products and Market Share
Key Offerings
- VOWST (fecal microbiota spores, live-brpk): VOWST is an FDA-approved oral microbiome therapy used to prevent recurrence of Clostridioides difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI. Market share data is still developing as the product recently launched. Competitors include Ferring Pharmaceuticals (REBYOTA) and synthetic options such as fecal transplants. Revenue data is growing post-launch.
Market Dynamics
Industry Overview
The microbiome therapeutics industry is a growing field focused on harnessing the power of the human microbiome to treat and prevent diseases. There is increasing interest and investment in this area.
Positioning
Seres is a pioneer in the microbiome therapeutics field, with the first FDA-approved oral microbiome therapy for CDI. This gives them a first-mover advantage and established expertise.
Total Addressable Market (TAM)
The TAM for microbiome therapeutics is estimated to be in the billions of dollars, with the CDI market representing a significant portion. Seres is well-positioned to capture a substantial share of this market with VOWST.
Upturn SWOT Analysis
Strengths
- First FDA-approved oral microbiome therapy
- Strong intellectual property portfolio
- Experienced management team
- Established manufacturing capabilities
Weaknesses
- Limited commercial track record
- High operating expenses
- Dependence on VOWST sales
- Uncertainty regarding long-term market acceptance of microbiome therapies
Opportunities
- Expansion of VOWST indications
- Development of new microbiome therapeutics
- Strategic partnerships and collaborations
- Increasing awareness and acceptance of microbiome therapies
Threats
- Competition from other microbiome therapeutics companies
- Regulatory hurdles
- Clinical trial failures
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- MRK
- FERRING
Competitive Landscape
Seres has the first oral product but faces competition from REBYOTA (Ferring) and larger pharmaceutical companies with broader market reach. Seres is attempting to gain market share due to ease of access with an oral medication as opposed to an enema.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth was primarily driven by research and development activities and collaborations. Revenue growth is now expected to be driven by VOWST sales.
Future Projections: Future projections depend heavily on the market adoption of VOWST and the success of pipeline programs. Analyst estimates vary depending on these factors.
Recent Initiatives: Recent initiatives include the commercial launch of VOWST, expansion of manufacturing capacity, and continued development of pipeline programs.
Summary
Seres Therapeutics is a pioneering microbiome therapeutics company with FDA approval for VOWST. Its success hinges on the successful commercialization of VOWST and the expansion of its pipeline. The company faces competition from other microbiome players and larger pharmaceutical companies. While Seres is on the right track, investors should closely monitor sales growth and financial performance.
Similar Companies
CRSP
Crispr Therapeutics AG
CRSP
Crispr Therapeutics AG
EDIT
Editas Medicine Inc
EDIT
Editas Medicine Inc
MRK
Merck & Company Inc
MRK
Merck & Company Inc
Sources and Disclaimers
Data Sources:
- Seres Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is based on available estimates and may not be precise. Investment decisions should be made based on individual risk tolerance and financial circumstances.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Seres Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2015-06-26 | President, CEO & Director Mr. Eric D. Shaff M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 103 | |
Full time employees 103 | |||
Seres Therapeutics, Inc., a clinical-stage company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. The company develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's product candidate is VOWST, the first FDA-approved orally administered microbiome therapeutic. Its product pipeline also includes SER-155, an investigational, oral, live biotherapeutic designed to decolonize gastrointestinal, or GI, pathogens, improve epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, or BSIs, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation, or allo-HSCT. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it develops SER-147, an investigational live biotherapeutic designed to prevent bacterial bloodstream and spontaneous bacterial peritonitis, or SBP, infections in patients with metabolic disease, including clinical liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.